Abstract
Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
